## Toshiaki Iba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2516980/publications.pdf Version: 2024-02-01



Тоснілкі Івл

#	Article	IF	CITATIONS
1	ISTH interim guidance on recognition and management of coagulopathy in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1023-1026.	3.8	1,513
2	Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology,the, 2020, 7, e438-e440.	4.6	1,186
3	Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Critical Care Medicine, 2005, 33, 368-372.	0.9	611
4	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 1859-1865.	3.8	547
5	A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria*. Critical Care Medicine, 2006, 34, 625-631.	0.9	512
6	Coagulopathy in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2103-2109.	3.8	453
7	Coagulopathy of Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1358-1364.	0.9	412
8	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	5.8	366
9	Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. Journal of Thrombosis and Haemostasis, 2018, 16, 231-241.	3.8	333
10	Diagnosis and management of sepsisâ€induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1989-1994.	3.8	325
11	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflammation Research, 2020, 69, 1181-1189.	4.0	302
12	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open, 2017, 7, e017046.	1.9	230
13	Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thrombosis Research, 2010, 125, 6-11.	1.7	222
14	Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey*. Critical Care Medicine, 2008, 36, 145-150.	0.9	205
15	Derangement of the endothelial glycocalyx in sepsis. Journal of Thrombosis and Haemostasis, 2019, 17, 283-294.	3.8	196
16	Morphological response of human endothelial cells subjected to cyclic strain in vitro. Microvascular Research, 1991, 42, 245-254.	2.5	188
17	DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Reviews, 2016, 30, 257-261.	5.7	139
18	A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care, 2013, 17, R297.	5.8	132

#	Article	IF	CITATIONS
19	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2019, 8, 728.	2.4	128
20	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2020, 46, 089-095.	2.7	124
21	ISTH guidelines for antithrombotic treatment in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	3.8	100
22	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology, 2020, 132, 1238-1245.	2.5	99
23	Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. PLoS ONE, 2014, 9, e85765.	2.5	99
24	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG) Tj ETQq0 0	0 rgBT /Ov	erlock 10 Tf
25	ALTERATIONS IN COAGULATION AND FIBRINOLYSIS DURING SEPSIS. Shock, 1996, 5, 223-228.	2.1	89
26	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	2.4	83
27	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. Critical Care, 2019, 23, 280.	5.8	79
28	Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically III Patients. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 71-76.	1.7	77
29	Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thrombosis Journal, 2018, 16, 14.	2.1	75
30	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Journal of Intensive Care, 2018, 6, 7.	2.9	74
31	Stimulation of endothelial secretion of tissue-type plasminogen activator by repetitive stretch. Journal of Surgical Research, 1991, 50, 457-460.	1.6	73
32	Neutrophil cell death in response to infection and its relation to coagulation. Journal of Intensive Care, 2013, 1, 13.	2.9	73
33	Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Medicine Experimental, 2015, 3, 36.	1.9	71
34	Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thrombosis Research, 2009, 123, 715-718.	1.7	70
35	Anticoagulant therapy for sepsisâ€associated disseminated intravascular coagulation: the view from Japan. Journal of Thrombosis and Haemostasis, 2014, 12, 1010-1019.	3.8	69
36	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	3.8	69

#	Article	IF	CITATIONS
37	COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Internal and Emergency Medicine, 2021, 16, 309-312.	2.0	68
38	Modulation of endothelial cell phenotype by cyclic stretch: Inhibition of collagen production. Journal of Surgical Research, 1990, 48, 415-420.	1.6	65
39	SIRS-ASSOCIATED COAGULOPATHY AND ORGAN DYSFUNCTION IN CRITICALLY ILL PATIENTS WITH THROMBOCYTOPENIA. Shock, 2007, 28, 411-417.	2.1	63
40	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. Thrombosis Research, 2012, 130, e129-e133.	1.7	63
41	Diagnosis of sepsisâ€induced disseminated intravascular coagulation and coagulopathy. Acute Medicine & Surgery, 2019, 6, 223-232.	1.2	63
42	Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surgery Today, 1995, 25, 585-590.	1.5	62
43	ASSOCIATION BETWEEN THE SEVERITY OF SEPSIS AND THE CHANGES IN HEMOSTATIC MOLECULAR MARKERS AND VASCULAR ENDOTHELIAL DAMAGE MARKERS. Shock, 2005, 23, 25-29.	2.1	61
44	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (Jâ€ <scp>SSCG</scp> 2016). Acute Medicine & Surgery, 2018, 5, 3-89.	1.2	61
45	Tissue Plasminogen Activator Expression in Endothelial Cells Exposed to Cyclic Strain in Vitro. Cell Transplantation, 1992, 1, 43-50.	2.5	60
46	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. Journal of Intensive Care Medicine, 2020, 35, 643-649.	2.8	60
47	The role of the endothelium in changes in procoagulant activity in sepsis. Journal of the American College of Surgeons, 1998, 187, 321-329.	0.5	58
48	Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice. International Immunology, 2016, 28, 245-253.	4.0	56
49	Defining traumaâ€induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 740-747.	3.8	56
50	COVIDâ€19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women's Health. Journal of Thrombosis and Haemostasis, 2020, 18, 3086-3098.	3.8	54
51	Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Critical Care, 2009, 13, R203.	5.8	53
52	Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. International Journal of Hematology, 2016, 103, 253-261.	1.6	53
53	Role of extracellular vesicles in the development of sepsis-induced coagulopathy. Journal of Intensive Care, 2018, 6, 68.	2.9	52
54	Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Thrombosis and Haemostasis, 2008, 100, 1099-1105.	3.4	51

#	Article	IF	CITATIONS
55	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Critical Care, 2016, 20, 287.	5.8	51
56	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical Care, 2014, 18, 497.	5.8	50
57	Differential diagnoses for sepsisâ€induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	3.8	50
58	Neutrophil extracellular traps induce IL-1β production by macrophages in combination with lipopolysaccharide. International Journal of Molecular Medicine, 2017, 39, 549-558.	4.0	48
59	A reâ€evaluation of the Dâ€dimer cutâ€off value for making a diagnosis according to the ISTH overtâ€DIC diagnostic criteria: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1442-1444.	3.8	48
60	COMPARISON OF THE PROTECTIVE EFFECTS OF TYPE III PHOSPHODIESTERASE (PDE3) INHIBITOR (CILOSTAZOL) AND ACETYLSALICYLIC ACID ON INTESTINAL MICROCIRCULATION AFTER ISCHEMIA REPERFUSION INJURY IN MICE. Shock, 2006, 26, 522-526.	2.1	47
61	ls the neutrophil a â€~prima donna' in the procoagulant process during sepsis?. Critical Care, 2014, 18, 230.	5.8	46
62	Recent advances in the research and management of sepsis-associated DIC. International Journal of Hematology, 2021, 113, 24-33.	1.6	46
63	Predicting the Severity of Systemic Inflammatory Response Syndrome (SIRS)-Associated Coagulopathy With Hemostatic Molecular Markers and Vascular Endothelial Injury Markers. Journal of Trauma, 2007, 63, 1093-1098.	2.3	43
64	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. Journal of Intensive Care, 2019, 7, 32.	2.9	42
65	Expression of hypoxia-inducible factor 1α gene affects the outcome in patients with ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 499-505.	2.5	41
66	The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thrombosis Research, 2013, 131, 383-389.	1.7	41
67	Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Reviews, 2016, 30, 149-155.	5.7	41
68	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thrombosis Research, 2019, 179, 11-14.	1.7	41
69	Evaluation of haemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections. Thrombosis and Haemostasis, 2006, 95, 282-287.	3.4	40
70	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 439-445.	1.7	40
71	Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. Thrombosis Research, 2018, 171, 1-6.	1.7	39
72	Laparoscopic Surgery for Left Paraduodenal Hernia. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2004, 14, 111-115.	1.0	37

#	Article	IF	CITATIONS
73	Proposal of a twoâ€step process for the diagnosis of sepsisâ€induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	3.8	37
74	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J‧SCG 2020). Acute Medicine & Surgery, 2021, 8, e659.	1.2	37
75	COVIDâ€19: Thrombosis, thromboinflammation, and anticoagulation considerations. International Journal of Laboratory Hematology, 2021, 43, 29-35.	1.3	37
76	PRETREATMENT OF SIVELESTAT SODIUM HYDRATE IMPROVES THE LUNG MICROCIRCULATION AND ALVEOLAR DAMAGE IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INFLAMMATION IN HAMSTERS. Shock, 2006, 26, 95-98.	2.1	35
77	Laparoscopy-Assisted Low Anterior Resection with a Prolapsing Technique for Low Rectal Cancer. Surgery Today, 2005, 35, 598-602.	1.5	34
78	Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. Journal of Intensive Care, 2014, 2, 66.	2.9	34
79	Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1020-1026.	1.7	32
80	Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsisâ€associated coagulopathy: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1618-1625.	3.8	32
81	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Archives of Medical Research, 2021, 52, 788-797.	3.3	32
82	Factor Xa-Inhibitor (Dx-9065a) Modulates the Leukocyte-Endothelial Cell Interaction in Endotoxemic Rat. Shock, 2002, 17, 159-162.	2.1	31
83	Antimicrobial cathelicidin peptide LL-37 induces NET formation and suppresses the inflammatory response in a mouse septic model. Molecular Medicine Reports, 2017, 16, 5618-5626.	2.4	31
84	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	4.9	31
85	Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. Thrombosis and Haemostasis, 2008, 100, 1099-105.	3.4	31
86	Human Host Defense Cathelicidin Peptide LL-37 Enhances the Lipopolysaccharide Uptake by Liver Sinusoidal Endothelial Cells without Cell Activation. Journal of Immunology, 2016, 196, 1338-1347.	0.8	30
87	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2022, 50, e80-e86.	0.9	30
88	Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan― Thrombosis Research, 2014, 134, 924-925.	1.7	29
89	High-Dose Antithrombin Therapy for Sepsis: Mechanisms of Action. Shock, 2002, 18, 389-394.	2.1	28
90	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends in Cardiovascular Medicine, 2022, 32, 249-256.	4.9	28

#	Article	IF	CITATIONS
91	The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thrombosis Research, 2015, 135, 897-901.	1.7	27
92	Frequency and hemostatic abnormalities in pre-DIC patients. Thrombosis Research, 2010, 126, 74-78.	1.7	26
93	The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation, 2020, 27, e12617.	1.8	26
94	Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. Journal of Intensive Care, 2017, 5, 40.	2.9	25
95	Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. Thrombosis Journal, 2019, 17, 12.	2.1	25
96	DIC in obstetrics: Diagnostic score, highlights in management, and international registry ommunication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1562-1566.	3.8	25
97	Laboratory haemostasis monitoring in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2058-2060.	3.8	25
98	Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thrombosis Research, 2014, 134, 169-173.	1.7	24
99	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882404.	1.7	24
100	Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Medicine, 2005, 31, 1101-1108.	8.2	22
101	Effect of Hemoperfusion Using Polymyxin B-Immobilized Fibers on Non-Shock Rat Sepsis Model. Journal of Surgical Research, 2011, 171, 755-761.	1.6	22
102	Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. Annals of Intensive Care, 2017, 7, 110.	4.6	22
103	Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Critical Care, 2019, 23, 302.	5.8	22
104	Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Critical Care, 2008, 12, R86.	5.8	21
105	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. EClinicalMedicine, 2022, 44, 101276.	7.1	21
106	Intracellular cyclic AMP levels in endothelial cells subjected to cyclic strain in vitro. Journal of Surgical Research, 1992, 52, 625-630.	1.6	20
107	Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thrombosis Research, 2013, 131, 295-299.	1.7	20
108	Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte–endothelial interaction and suppresses the increase of intrinsic damage–associated molecular patterns in endotoxemic rats. lournal of Surgical Research. 2014, 187, 581-586.	1.6	20

#	Article	IF	CITATIONS
109	Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer. Gynecologic Oncology, 2004, 93, 628-631.	1.4	19
110	Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. Journal of Trauma, 2012, 72, 177-182.	2.3	19
111	Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thrombosis Research, 2014, 133, 276-280.	1.7	19
112	Type and dose of heparin in Covidâ€19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 2063-2064.	3.8	19
113	ENOXAPARIN ATTENUATES ENDOTHELIAL DAMAGE WITH LESS BLEEDING COMPARED WITH UNFRACTIONATED HEPARIN IN ENDOTOXEMIC RATS. Shock, 2009, 32, 530-534.	2.1	18
114	Effect of cyclic stretch on endothelial cells from different vascular beds. Circulatory Shock, 1991, 35, 193-8.	0.6	18
115	Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model. Experimental and Therapeutic Medicine, 2017, 13, 2969-2974.	1.8	17
116	Ischemic limb necrosis in septic shock: What is the role of highâ€dose vasopressor therapy?. Journal of Thrombosis and Haemostasis, 2019, 17, 1973-1978.	3.8	17
117	DOACs and "newer―hemophilia therapies in COVIDâ€19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 1795-1796.	3.8	17
118	Endothelial Injury in COVID-19 and Acute Infections. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1774-1776.	2.4	17
119	Platelet Activation and Thrombosis in COVID-19. Seminars in Thrombosis and Hemostasis, 2023, 49, 055-061.	2.7	17
120	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thrombosis Research, 2016, 145, 46-50.	1.7	16
121	Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis. Journal of Intensive Care, 2017, 5, 56.	2.9	16
122	Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum. PLoS ONE, 2019, 14, e0222403.	2.5	16
123	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	3.8	16
124	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. International Journal of Hematology, 2021, 113, 330-336.	1.6	16
125	Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2021, 10, 2860.	2.4	16
126	The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS. Journal of Intensive Care, 2019, 7, 31.	2.9	15

#	Article	IF	CITATIONS
127	Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils. Innate Immunity, 2020, 26, 565-579.	2.4	15
128	Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 422-428.	1.7	14
129	Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. Journal of Clinical Medicine, 2022, 11, 985.	2.4	14
130	Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 677-684.	1.7	13
131	Effect of Hemoperfusion Using Polymyxin B-immobilized Fibers on Acute Lung Injury in a Rat Sepsis Model. International Journal of Medical Sciences, 2014, 11, 255-261.	2.5	12
132	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	2.5	12
133	Antithrombin Modulates the Leukocyte???Endothelial Cell Interaction in the Staphylococcal Enterotoxin B-Challenged Mouse. Journal of Trauma, 2003, 55, 546-550.	2.3	11
134	Neutrophil extracellular traps, damageâ€associated molecular patterns, and cell death during sepsis. Acute Medicine & Surgery, 2014, 1, 2-9.	1.2	11
135	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 145S-149S.	1.7	11
136	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. Thrombosis and Haemostasis, 2022, 122, 008-019.	3.4	11
137	Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. International Journal of Molecular Sciences, 2021, 22, 176.	4.1	10
138	Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 <i>In Vitro</i> . Microcirculation, 2016, 23, 240-247.	1.8	9
139	Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. International Journal of Hematology, 2018, 107, 528-534.	1.6	9
140	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. Trends in Cardiovascular Medicine, 2021, 31, 6-7.	4.9	9
141	Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation. British Journal of Haematology, 2010, 149, 461-462.	2.5	8
142	Factor <scp>X</scp> a Inhibitor Attenuates Leukocyte Adhesion and Thrombus Formation in an Experimental Mouse Model of the Metabolic Syndrome. Cardiovascular Therapeutics, 2013, 31, 280-284.	2.5	8
143	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thrombosis Journal, 2021, 19, 12.	2.1	8
144	WHAT CAN WE LEARN FROM THE THREE MEGATRIALS USING ANTICOAGULANTS IN SEVERE SEPSIS?. Shock, 2004, 22, 508-512.	2.1	7

#	Article	IF	CITATIONS
145	A case of cardiac arrest with ST elevation induced by contrast medium. American Journal of Emergency Medicine, 2012, 30, 2083.e3-2083.e4.	1.6	7
146	The authors reply. Critical Care Medicine, 2020, 48, e1160-e1161.	0.9	7
147	Thrombosis and Coronavirus Disease 2019: Controversies and (Tentative) Conclusions. Clinical Infectious Diseases, 2021, 73, 2294-2297.	5.8	7
148	Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study. Blood Purification, 2022, 51, 62-69.	1.8	7
149	New therapeutic options for patients with sepsis and disseminated intravascular coagulation. Polish Archives of Internal Medicine, 2014, 124, 321-328.	0.4	7
150	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Medica, 2022, 112, .	0.9	7
151	Formation of the venous thrombus after venous occlusion in the experimental mouse model of metabolic syndrome. Thrombosis Research, 2012, 129, e246-e250.	1.7	6
152	Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan. Journal of Thrombosis and Haemostasis, 2013, 11, 2076-2078.	3.8	6
153	The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage. Thrombosis Research, 2015, 135, 963-969.	1.7	6
154	Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. International Journal of Hematology, 2016, 103, 665-672.	1.6	6
155	Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 453-458.	1.7	6
156	Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary by utilizing two scoring systems. Blood Coagulation and Fibrinolysis, 2019, 30, 11-16.	1.0	6
157	High-Dose Antithrombin Therapy for Sepsis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 49, 979-980.	2.4	5
158	Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	5
159	The application of anticoagulant therapy to sepsis. Journal of Intensive Care, 2017, 5, 32.	2.9	5
160	Does TeamSTEPPS affect psychological status?. International Journal of Health Care Quality Assurance, 2019, 32, 11-20.	0.9	5
161	Oh, how hard it is to open the gate for sepsis trials: lessons from <scp>SCARLET</scp> . Acute Medicine & Surgery, 2019, 6, 3-4.	1.2	5
162	Role of DIC in multiple organ failure. International Journal of Surgical Investigation, 2000, 2, 73-80.	0.0	5

#	Article	IF	CITATIONS
163	The meanings of DIC diagnostic criteria. Thrombosis Research, 2012, 129, e269-e270.	1.7	4
164	Analysis of nonâ€ŧraumatic truncal back pain in patients who visited an emergency room. Acute Medicine & Surgery, 2014, 1, 94-100.	1.2	4
165	Glycocalyx Regulates the Intravascular Hemostasis. Juntendo Medical Journal, 2016, 62, 330-335.	0.1	4
166	Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?. Intensive Care Medicine, 2016, 42, 1193-1194.	8.2	4
167	The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro. TH Open, 2017, 01, e3-e10.	1.4	4
168	Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962094111.	1.7	4
169	The efficacy of long-term oral chemotherapy with 5?-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. International Journal of Clinical Oncology, 2004, 9, 383-387.	2.2	3
170	Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. Journal of Thrombosis and Haemostasis, 2015, 13, 682-683.	3.8	3
171	Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods. Therapeutics and Clinical Risk Management, 2019, Volume 15, 791-802.	2.0	3
172	Reply to "Errors in the diagnosis for DIC due to a statistical misunderstanding― Journal of Thrombosis and Haemostasis, 2020, 18, 1792-1793.	3.8	3
173	A case of Juvenile polyposis localized in the stomach accompanied by anemia and hypoproteinemia. Progress of Digestive Endoscopy, 2001, 59, 52-55.	0.0	3
174	Protective effects of antithrombin III on organ dysfunction induced by the continuous infusion of endotoxin in rats Nihon Kyukyu Igakukai Zasshi, 1998, 9, 45-52.	0.0	3
175	A case of paraparesis with thoracic ossification of the posterior longitudinal ligament and the ligamentum flavum induced by falling down on the abdomen. Acute Medicine & Surgery, 2014, 1, 54-57.	1.2	2
176	Is Postoperative Polymyxin B Hemoperfusion for Abdominal Septic Shock Really Ineffective?. Critical Care Medicine, 2014, 42, e596-e597.	0.9	2
177	Diagnosis of Sepsis by Al-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks. Applied Sciences (Switzerland), 2021, 11, 1967.	2.5	2
178	A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. Journal of Critical Care, 2021, 64, 108-113.	2.2	2
179	Title is missing!. Japanese Journal of Thrombosis and Hemostasis, 2001, 12, 32-38.	0.1	2
180	Title is missing!. Journal of the Japanese Society of Intensive Care Medicine, 2004, 11, 193-199.	0.0	2

#	Article	IF	CITATIONS
181	The current status of the therapeutic approach for severe sepsis in Japan and its comparison to the international guidelines. Nihon Kyukyu Igakukai Zasshi, 2009, 20, 915-922.	0.0	2
182	COVID-19-associated coagulopathy and thrombosis. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 600-603.	0.1	2
183	The Obstacles That Should be Overcome to Develop New Anticoagulants for Severe Sepsis. Critical Care Medicine, 2014, 42, e248-e249.	0.9	1
184	Glycocalyx damage and microcirculatory disturbance. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 726-732.	0.1	1
185	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€induced coagulopathy than fibrinâ€related markers: Response to the Letterâ€toâ€theâ€Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	3.8	1
186	Activated protein C suppresses the production of pro-inflammatory cytokines and the leukocyte-endothelial interaction in rat LPS model. Journal of the Japanese Society of Intensive Care Medicine, 2005, 12, 191-195.	0.0	1
187	Biochemical modulation for 5 -FU No. 2. Juntendoì,, Igaku, 1996, 42, 113-120.	0.1	1
188	Glycocalyx regulates the intravascular hemostasis. Japanese Journal of Thrombosis and Hemostasis, 2016, 27, 444-449.	0.1	1
189	Controversies regarding the use of antithrombin for sepsis-associated disseminated intravascular coagulation: an update of the evidence. Blood Transfusion, 2015, 13, 166.	0.4	1
190	EFFECTS OF ANTITHROMBIN ON VASOACTIVE SUBSTANCES PRODUCTION IN ENDOTOXEMIC RATS Shock, 1999, 12, 38.	2.1	0
191	COMPARISON OF THE PROTECTIVE EFFECTS OF CILOSTAZOL AND ACETYLSALICYLIC ACID ON INTESTINAL MICROCIRCULATION AFTER ISCHEMIA REPERFUSION INJURY. Shock, 2006, 25, 38.	2.1	0
192	A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis. Chest, 2013, 144, 418A.	0.8	0
193	A Case of Lung Lesions Induced by a soccer Ball. Clinical Medicine Insights: Trauma and Intensive Medicine, 2013, 4, CMTIM.S11818.	0.2	0
194	Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation. Critical Care, 2015, 19, 233.	5.8	0
195	Bleeding complications of anticoagulant therapy in sepsis-induced disseminated intravascular coagulation. Critical Care, 2016, 20, 307.	5.8	0
196	Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC?. Intensive Care Medicine, 2017, 43, 152-153.	8.2	0
197	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.9	0
198	The Unbalance of Coagulation/Fibrinolysis and Microcirculatory Disturbance in Sepsis. Japanese Journal of Thrombosis and Hemostasis, 2000, 11, 229-235.	0.1	0

#	Article	IF	CITATIONS
199	Physiological protease inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2006, 17, 314-319.	0.1	0
200	The Current Status of Sepsis Research in Japan in Comparison to the Status of International Research. Juntendol,, Igaku, 2010, 56, 334-338.	0.1	0
201	Conceptual change of the septic disseminated intravascular coagulation and the progress in its treatment. Nihon Kyukyu Igakukai Zasshi, 2011, 22, 37-45.	0.0	0
202	Disaster Medicine Education and Training for Medical Student at Juntendo University. Juntendo Medical Journal, 2014, 60, 112-118.	0.1	0
203	A CASE REPORT OF SPINDLE CELL CARCINOMA IN BILATERAL SYNCHRONOUS BREAST CANCER. The Journal of the Japanese Practical Surgeon Society, 1989, 50, 1149-1154.	0.0	0
204	The significance of humoral mediators in gram-positive infection Nihon Kyukyu Igakukai Zasshi, 1993, 4, 291-298.	0.0	0
205	Changes in plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in sepsis with organ failure Nihon Kyukyu Igakukai Zasshi, 1994, 5, 365-372.	0.0	0
206	Imbalance between coagulation and fibrinolysis in sepsis Nihon Kyukyu Igakukai Zasshi, 1995, 6, 25-32.	0.0	0
207	Biochemical modulation for 5 -FU No. 1. Juntendol̀,, Igaku, 1996, 41, 492-499.	0.1	0
208	Evaluation of a rat model for disseminated intravascular coagulation developed by infusion of lipopolysaccharide Nihon Kyukyu Igakukai Zasshi, 1997, 8, 103-110.	0.0	0
209	Alterations in circulating levels of soluble intercellular adhesion molecule-1 in sepsis Nihon Kyukyu Igakukai Zasshi, 1997, 8, 161-167.	0.0	0
210	Changes in Circulating Levels of Tissue Factor and Tissue Factor Pathway Inhibitor in SIRS, Septic MODS and Septic DIC Nihon Kyukyu Igakukai Zasshi, 1997, 8, 650-658.	0.0	0
211	Effects of total parenteral nutrition(TPN) supplemented with medium-chain triglyceride(MCT) in rats with endotoxin-induced sepsis Nihon Kyukyu Igakukai Zasshi, 1997, 8, 288-296.	0.0	0
212	Improvement in Sinusoidal Circulation with Supplement of Antithrombin III in Endotoxemic Rats Nihon Kyukyu Igakukai Zasshi, 1998, 9, 579-586.	0.0	0
213	Changes in protein C activity in severe sepsis Nihon Kyukyu Igakukai Zasshi, 1998, 9, 294-300.	0.0	0
214	The effect of recombinant thrombomodulin on disseminated intravascular coagulation associated with acute pancreatitis. Journal of the Japanese Society of Intensive Care Medicine, 2015, 22, 402-403.	0.0	0
215	Clinical Elective Study Report at the Department of Emergency and Critical Care Medicine in Juntendo University Faculty of Medicine. Juntendo Medical Journal, 2015, 61, 166-170.	0.1	0
216	Thrombin-Antithrombin System. , 2021, , 43-51.		0

Thrombin-Antithrombin System., 2021, , 43-51. 216

#	Article	IF	CITATIONS
217	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. Journal of Intensive Care, 2022, 10, 4.	2.9	0